[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,424,438
  • Shares Outstanding, K 199,782
  • Annual Sales, $ 5,141 M
  • Annual Income, $ 1,287 M
  • EBIT $ 1,611 M
  • EBITDA $ 1,704 M
  • 60-Month Beta 0.76
  • Price/Sales 4.53
  • Price/Cash Flow 18.87
  • Price/Book 4.14

Options Overview Details

View History
  • Implied Volatility 38.56% (-1.24%)
  • Historical Volatility 37.01%
  • IV Percentile 60%
  • IV Rank 34.28%
  • IV High 64.77% on 10/31/25
  • IV Low 24.90% on 08/08/25
  • Expected Move (DTE 32) 8.87 (7.67%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 365
  • Volume Avg (30-Day) 1,186
  • Put/Call OI Ratio 1.58
  • Today's Open Interest 19,682
  • Open Int (30-Day) 17,511
  • Expected Range 106.78 to 124.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.61
  • Number of Estimates 7
  • High Estimate $1.95
  • Low Estimate $1.25
  • Prior Year $1.31
  • Growth Rate Est. (year over year) +22.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
99.79 +15.89%
on 06/22/26
119.60 -3.30%
on 07/17/26
+17.43 (+17.75%)
since 06/18/26
3-Month
92.18 +25.46%
on 06/02/26
119.60 -3.30%
on 07/17/26
+18.73 (+19.33%)
since 04/20/26
52-Week
67.17 +72.18%
on 07/21/25
119.60 -3.30%
on 07/17/26
+47.79 (+70.42%)
since 07/18/25

Most Recent Stories

More News
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

Agreement provides Incyte the rights to develop and commercialize ENHANZE ® with its mutCALR development program and an option to nominate up to two additional targets

INCY : 115.65 (-1.36%)
HALO : 77.09 (-0.93%)
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolio Both INCB161734, an investigational,...

INCY : 115.65 (-1.36%)
What to Expect From Incyte's Q2 2026 Earnings Report

Incyte is scheduled to release its second-quarter results later this month, with analysts projecting a double-digit increase in its bottom line figure.

XLV : 159.25 (-1.14%)
$SPX : 7,443.28 (-0.19%)
INCY : 115.65 (-1.36%)
Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings?

Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings?

INCY : 115.65 (-1.36%)
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

- Treatment with latarcibart led to an 81% median reduction in annualized bleeding rate (ABR) across all bleeding categories and patient types with von Willebrand disease (VWD) ...

INCY : 115.65 (-1.36%)
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

INCY : 115.65 (-1.36%)
Incyte to Report Second Quarter Financial Results

Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. The schedule for the press...

INCY : 115.65 (-1.36%)
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

Acquisition adds VGA039, a novel investigational monoclonal antibody in Phase 3 development for patients with von Willebrand disease (VWD), strengthening Incyte’s late-stage pipeline

INCY : 115.65 (-1.36%)
1 Mid-Cap Stock to Research Further and 2 We Avoid

1 Mid-Cap Stock to Research Further and 2 We Avoid

WSM : 223.34 (-2.22%)
INCY : 115.65 (-1.36%)
DRI : 194.82 (-1.87%)
1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn Down

1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn Down

INCY : 115.65 (-1.36%)
PAYC : 149.71 (+1.20%)
OII : 42.82 (+1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 121.58
2nd Resistance Point 120.11
1st Resistance Point 117.88
Last Price 115.65
1st Support Level 114.19
2nd Support Level 112.72
3rd Support Level 110.49

See More

52-Week High 119.60
Last Price 115.65
Fibonacci 61.8% 99.57
Fibonacci 50% 93.38
Fibonacci 38.2% 87.20
52-Week Low 67.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.